B2-R-bradykinin agonist-a novel approach in the treatment of cardiovascular diseases

Shaziya Afreen; Zainab Mahveen

Shaziya Afreen B. Pharmacy, Deccan School of Pharmacy.
Zainab Mahveen Department of Pharmacology-Deccan School of Pharmacy.

Abstract

Bradykinins are the most potent biologically active peptides located in vascular smooth muscle. The continuous advances in the characteristics of bradykinin receptors through development of selective receptor and molecular biology techniques aids to the rational design of drug effective in the treatment of cardiovascular diseases. BK B(2) receptor is not only implicated in the pathogenesis of inflammation, pain and tissue injury that also in powerful cardio protective mechanisms to treat and prevent various CV disorders such as hypertension, CHF, venous thrombosis, ventricular hypertrophy, ischemic heart disease. Several preclinical studies have been conducted using pharmacological agonist by which it was found that B(1)R have noxious effects whereas B(2)R have an important role in the process of coronary artery disease(CAD) and ischemic post conducting that limits the ischemia/reperfusion injury of the myocardium. However, none of the currently potent selective and non peptide agonists of BK B(2) receptors-JMV 1116(Fournier), RMP-7(lobradamil), FR-190997(Fujisawa) have been selected for the clinical assessment in cardiovascular indications. We therefore conclude that the treatment with potent and highly selective B2 receptor agonist, initiated immediately after the occurrence of acute ischemic event, should be explored as a potent therapeutic option in these circumstances .One of the major challenge is still an unanswered question that which of the mechanisms cardio protective (or) inflammation is extensively shown by BK B (2) receptor agonist. The following review will throw light on this discussion.

Keywords: Bradykinin, cardiac heart failure, coronary artery disease, cardio vascular disorders

Downloads

Download data is not yet available.

References

1. Rocha e Silva M, Beraldo WT, Rosenfeld G. Bradykinin a hypotensive and smooth muscle stimulating factor released from plasma globulin by snake venoms and by trypsin. Am J physiol 1949; 156:261-273.
2. Carretero OA, Scilli AG. Local hormonal factors (intracine, autocrine, and paracrine) in hypertension. Hypertension 1991; 18:158-169.
3. Sharma JN, Sharma J. Cardiovascular properties of the kallikrein-kinin system. Curr Med Res Opin. 2002; 18:10-17.
4. Sharma JN. Does the kinin system mediate in cardiovascular abnormalities? An overview. J Clin Pharmacol. 2003; 43:1187-1195.
5. Campbell DJ. The kallikrein-kinin system in humans. Clin Exp Pharmacol Physiol. 2001; 28:1060-1065.
6. Muller-Esterl, W., S. Iwanaga and S. Nakanishi. Kininogen revisited. Trends Pharmacol. Sci, 1986; 11:336-339.
7. Sharma, JN. The role of kallikrein-kinin system in joint inflammatory disease. Eur. J. Rheumatol. Inflamm. 1991; 11:30-36.
8. Mutschler Ernst, schafer korting Monika: Drugs interactions pharmacology and toxicology. Journal of American sciences 1997; 7:911.
9. Parpura V, Basarsky TA, Liu F, Jeftinija K, jeftinija S, Haydon PG. Glutamate-mediated astrocyte-neuron signaling. Nature 1994; 369 (6483):744-7. doi: 10. 1038/3697440.
10. Bas M, Adams V, Suvorava T, Niehues T, Hoffmann TK, Kojda G. Nonallergic angiodema: role of bradykinin. Allergy 2007; 62 (8):842-56.
11. McLean PG, Ahluwalia A, Perretti M. Association between kinin B1 Receptor Expression and Leukocyte Trafficking across Mouse Mesenteric Postcapillary Venules. J. Exp. Med. 2000; 192 (3):367-80.
12. Duchene J, Lecomte F, Ahmed S, Cayla C, Pesquero J, Bader M, Perretti M, Ahluwalia A. A novel inflammatory pathway involved in leukocyte recruitment: role for the kinin B1 receptor and the chemokine CXCL5. J. Immunol. 2007; 179 (7): 4849-56.
13. Farmers And R.M. Burch. Biochemical and molecular pharmacology of kinin receptors. Ann. Rev. Pharmacol Toxicol 1992; 32: 511-536.
14. Burch, R.M. Kinin signal transduction role of phosphoinositides and eicosanoids. J. Cardiov. Pharmacol 1990; 15:S44-S46.
15. Akbar, A, J.N. Sharma, A.P.M. Yusof and E.k. Gan. Potentiation of bradykinin-induced responses in the intact and deduded epitheliaum of guinea pig tracheal preparations. Tissue Reactions 1998; 20(3):95-100.
16. Schini, V.B., C. Boulanger and D. Regoli et al. Bradykinin stimulates the production of cyclic GMP via activation of B2 reeceptors in cultured porcine aortic enodothelial cells. J. Pharmacol. Expl. Ther. 1990; 43:1823-1827.
17. KD Tripathi: Essentials of medical pharmacology, seveth edition 509-511.
18. Ueno A, Naraba H, Kojima F, Morita E, Ohishi S. FR-190997, anovel bradykinin B2 agonist, expresses longer action than bradykinin in paw edema formation and hypotensive response. Immunopharmacology 1999; 45:89-93.
19. Heitsch H. The therapeutic potential of bradykinin B2 receptor agonists in the treatment of cardiovascular disease. Expert Opin Investig Drugs 2003, 12:759-770.
20. Morgolius, H.S., R.Geller and W. dejong et al. Altered urinary kallilrein excretion in rats hypertension. Cir. Res. 1972; 30:358-362.
21. Sharma, J.N., S.S. Amrah and A.R. Noor. Suppression of hypotensive response of captopril and enalapril by kallilrein inhibitor aprotinin in spontaneously hypertensive rats. Pharmacology 1995; 50:363-369.
22. Chao, J. and L. Chao. Kallikrein gene therapy in hypertension, cardiovascular and renal diseases. Gen. Ther. Mol. Biol. 1998; 1:301-308.